Exchange: NASDAQ·Updated 01:45 PM EDT
News
all
press releases
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
More News
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April
PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest...
MarketBeat
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...
MarketBeat
Why Is PDS Biotechnology Stock Gaining Wednesday?
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...
Benzinga
PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer
The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.
Stocktwits
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval
Stocktwits
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026
Stocktwits
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus
Zacks

Advertisement|Remove ads.